Natural Investments LLC Purchases 398 Shares of Medtronic PLC $MDT

Natural Investments LLC boosted its position in Medtronic PLC (NYSE:MDT) by 10.9% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 4,057 shares of the medical technology company’s stock after purchasing an additional 398 shares during the period. Natural Investments LLC’s holdings in Medtronic were worth $353,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Brighton Jones LLC grew its position in shares of Medtronic by 1,368.0% during the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock valued at $3,194,000 after acquiring an additional 37,265 shares during the period. GAMMA Investing LLC grew its position in shares of Medtronic by 41.1% during the 1st quarter. GAMMA Investing LLC now owns 15,882 shares of the medical technology company’s stock valued at $1,427,000 after acquiring an additional 4,626 shares during the period. Relyea Zuckerberg Hanson LLC grew its position in shares of Medtronic by 28.5% during the 1st quarter. Relyea Zuckerberg Hanson LLC now owns 4,014 shares of the medical technology company’s stock valued at $361,000 after acquiring an additional 890 shares during the period. Everhart Financial Group Inc. bought a new position in shares of Medtronic during the 1st quarter valued at approximately $267,000. Finally, Stanley Laman Group Ltd. grew its position in shares of Medtronic by 11.4% during the 1st quarter. Stanley Laman Group Ltd. now owns 3,137 shares of the medical technology company’s stock valued at $282,000 after acquiring an additional 321 shares during the period. 82.06% of the stock is owned by institutional investors.

Medtronic Stock Performance

NYSE MDT opened at $95.52 on Friday. Medtronic PLC has a 1 year low of $79.29 and a 1 year high of $99.37. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.01 and a quick ratio of 1.50. The stock has a market capitalization of $122.52 billion, a PE ratio of 26.31, a P/E/G ratio of 2.51 and a beta of 0.78. The company’s 50 day simple moving average is $93.56 and its two-hundred day simple moving average is $88.74.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.03. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The business had revenue of $8.58 billion for the quarter, compared to analysts’ expectations of $8.37 billion. During the same period in the prior year, the company posted $1.23 EPS. The business’s revenue for the quarter was up 7.7% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. Analysts predict that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 17th. Shareholders of record on Friday, September 26th will be paid a $0.71 dividend. The ex-dividend date is Friday, September 26th. This represents a $2.84 annualized dividend and a yield of 3.0%. Medtronic’s dividend payout ratio is currently 78.24%.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the stock. Morgan Stanley reissued an “overweight” rating and set a $107.00 target price (up from $98.00) on shares of Medtronic in a research report on Tuesday, July 15th. Royal Bank Of Canada restated an “outperform” rating and set a $111.00 price target on shares of Medtronic in a research note on Friday. Leerink Partnrs upgraded shares of Medtronic to a “strong-buy” rating in a research note on Monday, June 16th. William Blair upgraded shares of Medtronic to a “hold” rating in a research note on Friday, July 11th. Finally, Evercore ISI upped their price target on shares of Medtronic from $103.00 to $106.00 and gave the company an “outperform” rating in a research note on Tuesday, July 8th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $102.41.

Insider Activity at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 8,605 shares of the stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total value of $788,045.90. Following the sale, the executive vice president directly owned 35,615 shares in the company, valued at $3,261,621.70. This represents a 19.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director William R. Jellison bought 2,500 shares of the stock in a transaction on Monday, August 25th. The stock was purchased at an average price of $92.37 per share, for a total transaction of $230,925.00. Following the completion of the purchase, the director directly owned 5,000 shares in the company, valued at approximately $461,850. This represents a 100.00% increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 0.26% of the company’s stock.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.